Vascular endothelial growth factor receptor 3 (VEGFR3) (VEGFR3)

Vascular endothelial growth factor receptor 3 (VEGFR-3) is a transmembrane receptor tyrosine kinase that serves as the principal molecular regulator of the lymphatic system. While 'Lymphatic circulation acceleration' describes a physiological process or therapeutic goal, VEGFR-3 is the primary target through which this effect is pharmacologically controlled. In healthy tissues, VEGFR-3 signaling is essential for the growth and maintenance of lymphatic vessels (lymphangiogenesis), fluid homeostasis, and the transport of immune cells (Tammela & Alitalo, 2010). In clinical medicine, therapeutic agonists such as VEGF-C gene therapy (e.g., Lymfactin) are under investigation to accelerate lymphatic circulation and treat chronic lymphedema (Herantis Pharma, 2024). Conversely, VEGFR-3 is frequently upregulated in various cancers, where it facilitates the development of lymphatic vessels that act as conduits for the metastatic spread of tumor cells to regional lymph nodes; consequently, VEGFR-3 inhibitors are utilized as anti-tumor and anti-angiogenic agents (Stacker et al., 2004). The receptor's high specificity to the lymphatic endothelium makes it a critical focal point for research in vascular medicine, oncology, and inflammatory disorders (Rockson, 2019).

Other names

Fms-related tyrosine kinase 4FLT4Vascular endothelial growth factor receptor 3PCLLMPH1A

Activation of VEGFR-3 by its ligands VEGF-C or VEGF-D induces receptor dimerization and autophosphorylation, triggering signaling cascades (e.g., MAPK/ERK and PI3K/Akt pathways) that promote lymphatic endothelial cell proliferation and vessel growth. Agonists aim to accelerate lymphatic drainage in lymphedema, while small-molecule inhibitors block these pathways to prevent tumor-associated lymphangiogenesis and metastasis.